INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines

Immutep (IMMP) faces a new securities class action alleging securities fraud/unlawful business practices following a March 13, 2026 IDMC recommendation to discontinue its TACTI-004 Phase III trial for futility. Immutep’s ADR collapsed $2.27, or 82.44%, to close at $0.48 per ADR on the trial discontinuation news. The lawsuit filing increases legal overhang as investors reassess the company’s clinical outlook.

Analysis

This is less a legal event than a capital-structure event: once the lead program is effectively disqualified, the equity is no longer pricing a development story but a shrinking set of residual claims. In microcap biotech, that usually means the biggest damage comes from financing terms and investor base collapse, not from any eventual lawsuit payout; the class action is mostly a long-dated overhang with little near-term monetization.

The next 1-3 months are likely driven by market plumbing rather than court milestones. Watch for Nasdaq compliance pressure, reverse-split risk, going-concern language, and any distressed financing attempt; those are the mechanisms that can force additional selling and erase remaining equity value even if the stock already looks impaired. On the other side, any bounce is more likely to be a low-float squeeze than a fundamental rerating, so rallies should be treated as liquidity events unless management can show a credible non-flagship asset and adequate runway.

Second-order, this kind of failure modestly benefits large-cap oncology incumbents with approved regimens by keeping capital and physician mindshare anchored in established standards of care. The contrarian point is that the headline risk from the lawsuit is probably overestimated relative to the actual scientific failure, but the market may still underappreciate the probability of a capital event that wipes out the residual option value before any legal process matters. The key falsifier is disclosure of a longer-than-expected cash runway or a strategic transaction that effectively reassigns the remaining pipeline value away from dilution.

Key Decisions for Investors

• No new long exposure in IMMP; the risk/reward is dominated by dilution and delisting mechanics, not litigation optionality.
• If borrow and liquidity are workable, use any 1-2 week reflexive rally to short IMMP into strength rather than at the open; target bounce-driven entries near $0.60-$0.70, with a tight stop if management announces a credible asset sale or partnership.
• Set an alert on the next filing for cash runway and going-concern disclosure; if runway is <12 months, the short thesis strengthens materially and the equity likely remains a funding overhang.
• Avoid sector contagion trades for now; this is idiosyncratic, so XBI/IWM hedges are likely unnecessary unless broader biotech risk sentiment is already deteriorating.